Brief: Bergenbio Presents Encouraging Combined Data For Bemcentinib From Two Phase II COVID-19 Studies

Oncoinvent ASA

12/07/2021 13:15

July 12 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO PRESENTS ENCOURAGING COMBINED DATA FOR
BEMCENTINIB
FROM TWO PHASE II COVID-19 STUDIES AT ECCMID
    * SIGNIFICANTLY REDUCED LIKELIHOOD (69%) OF PROGRESSION TO
VENTILATION IN HIGHER SEVERITY COHORT
    * PRECLINICAL ANALYSIS HIGHLIGHTS BEMCENTINIB'S POTENTIAL
AGAINST
COVID-19 VARIANTS
    * SIGNIFICANTLY INCREASED LIKELIHOOD (88%) OF SHORTER TIME
TO
RECOVERY OR DISCHARGE IN HIGHER SEVERITY COHORT
    * SURVIVAL 96.6% VERSUS 91.2%

Source text for Eikon:  ID:nWkr3KkZxC 
Further company coverage:  BGBIO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))